However, in contrast to the Eμ-myc lymphoma model, all of the four c-myc amplified sensitive cell lines harbor mutations in p53 suggesting that sensitivity to Chk1 inhibitors may not be dependent on a p53 wild type background. The gene discussed is TP53; the disease is lymphoma.